

DEBATE

Open Access

Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease

Matthias Löhle* and Heinz Reichmann

Abstract

Background: Early initiation of pharmacotherapy in Parkinson's disease (PD) is nowadays widely advocated by experts since the delay of treatment has shown to be associated with a significant deterioration of health related quality of life in affected patients. Due to marked advances in PD treatment during the last decades, physicians are nowadays fortunately equipped with a variety of substances that can effectively ameliorate emerging motor symptoms of the disease, among them levodopa, dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors. Despite numerous drug intervention trials in early PD, there is however still ongoing controversy among neurologists which substance to use for the initial treatment of the disease.

Discussion: In multiple studies, MAO-B inhibitors, such as selegiline and rasagiline, have shown to provide mild symptomatic effects, delay the need for levodopa, and to reduce the incidence of motor fluctuations. Although their symptomatic efficacy is inferior compared to dopamine agonists and levodopa, MAO-B inhibitors undoubtedly have fewer side effects and are easy to administer. In contrary to their competitors, MAO-B inhibitors may furthermore offer a chance for disease modification, which so far remains a major unmet need in the management of PD and eventually makes them ideal candidates for the early treatment of the disease.

Summary: MAO-B inhibitors may constitute a preferable therapeutic option for early PD, mainly due to their favourable safety profile and their putative neuroprotective capabilities. Since the symptomatic effects of MAO-B inhibitors are comparatively mild, dopamine agonists and levodopa should however be considered for initial treatment in those PD patients, in whom robust and immediate symptomatic relief needs to be prioritized.

Background

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease and estimated to affect about 1-2% of the population over 65 years [1]. Early treatment of emerging symptoms is nowadays widely recommended, since PD patients left untreated at diagnosis show a significant worsening in their health related quality of life in comparison to those patients in whom treatment is initiated at or soon after diagnosis [2]. Furthermore, it has been proposed that early treatment of PD may be associated with a correction of basal ganglia functional abnormalities caused by dopaminergic cell loss and

dopamine deficiency and could therefore support intrinsic physiological compensatory mechanisms during the course of the disease [3].

Once PD has been diagnosed, physicians eventually find themselves faced by the question, which substance to choose for the initial treatment of the disease. Fortunately, we are nowadays provided with a variety of substances that can effectively counteract the motor symptoms of the disease, among them levodopa, dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors. In the following synopsis, we would like to address why MAO-B inhibitors could be preferred in this situation and may constitute the best option for the initial treatment of PD.

* Correspondence: matthias.loehle@uniklinikum-dresden.de
Department of Neurology, University Hospital Carl Gustav Carus, Dresden
University of Technology, Fetscherstrasse 74, 01307 Dresden, Germany

Discussion

MAO-B inhibitors provide mild symptomatic effects in early PD

Several large-scale, randomized placebo-controlled clinical trials have demonstrated that treatment with MAO-B inhibitors leads to a symptomatic amelioration of early PD [4-9]. For example, daily treatment with 10 mg selegiline (*N*-Propargylmethamphetamine) in the Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism (DATATOP) study was associated with an improvement of about 3 points on the total Unified Parkinson's Disease Rating Scale (UPDRS) and 1.7 points on the motor subscale of the UPDRS compared to placebo after 3 months [4]. Symptomatic effects of similar extent have been observed with the second-generation MAO-B inhibitor rasagiline (*N*-Propargyl-1[R]aminodan), which for example in the TVP-1012 in early monotherapy for PD outpatients (TEMPO) study led to an improvement of about 3 points on the total UPDRS after 3 months at a daily dose of 1 mg per day [5]. Although it can be argued that the symptomatic effects of MAO-B inhibitors may not reach a clinically meaningful magnitude [10] and are clearly inferior in comparison to those seen with modern dopamine agonists [11-14] or even the gold-standard levodopa [15,16], MAO-B inhibitors may still be good candidates for initial PD treatment, since they are able to attenuate the usually mild motor symptoms during the early phase of PD, thereby facilitating the sparing of symptomatically stronger agents for later stages of the disease, when the magnitude of motor impairment ultimately requires more robust symptomatic action. Indeed, multiple studies have successfully demonstrated that early treatment with the MAO-B inhibitors selegiline or lazabemide is capable to delay the need to start with levodopa in PD patients [4,8,9,17-19]. Since long-term levodopa treatment is known to be associated with motor complications, the levodopa-sparing effect of MAO-B inhibitors is likely to be beneficial in the long run, although clinical studies so far failed to prove an antidyskinetic effect of MAO-B inhibition, which may have been due to wide confidence intervals in these studies [20]. However, clinical studies have demonstrated that primary treatment with the MAO-B inhibitor selegiline reduces the incidence of motor fluctuations compared to placebo [21] as well as to levodopa treatment [22]. Similarly, initial monotherapy with the dopamine agonists ropinirole and pramipexole has shown to significantly decrease the incidence of dyskinesias and to a lesser extent also motor fluctuations [23,24]. However, this did not translate into a benefit in terms of overall function or quality of life in comparison to patients that were initially treated with levodopa [23,24], which somewhat argues

against a general preference of dopamine agonists over other antiparkinsonian agents in the early stages of PD. In summary, initial treatment with MAO-B inhibitors provides a mild effect on motor symptoms in patients with early PD, delays the need for levodopa, reduces the incidence of motor fluctuations and may furthermore turn out advantageous from a strategic perspective, since it enables physicians to counteract emerging symptoms of early PD without already utilizing the strongest symptomatic options at the very beginning. Due to their superior symptomatic efficacy, dopamine agonists and levodopa should however be considered for initial treatment particularly in those PD patients, who require immediate and robust symptomatic control of their motor symptoms.

MAO-B inhibitors are well tolerated

When PD patients are subjected to chronic pharmacological treatment for the first time, side effects of the initial therapy will have a major impact on their judgement of antiparkinsonian agents and eventually also be crucial for long-term adherence to PD treatment. Thus, it seems wise to choose an antiparkinsonian agent for initial treatment that provides both symptomatic efficacy and an advantageous side-effect profile. The use of dopamine agonists is often accompanied by adverse events such as nausea, dizziness, somnolence, oedema and hallucinations, which in long-term clinical studies led to substantial drop rates of about 30 to 40% [23,25]. Although treatment with levodopa is considered to be safe and well tolerated, comparative studies between levodopa and dopamine agonists found similar drop rates due to side effects in levodopa treated patients as with dopamine agonists [23,25]. Furthermore, long-term administration of levodopa is known to be associated with motor complications, such as dyskinesia and wearing-off [15,26], which argues against its early use in PD.

On the contrary, clinical studies have demonstrated that MAO-B inhibitors are well tolerated and usually do not cause substantial side effects [20]. Although the use of selegiline has been associated with adverse events like anorexia, nausea, dry mouth, dyskinesia, musculoskeletal injuries, hallucinations, cardiac arrhythmias and orthostatic hypotension, which may be due to an augmentation of dopaminergic activity or amphetamine metabolites of selegiline [27-31], it is important to note that a meta-analysis of placebo-controlled trials found no difference in dropouts due to adverse events between patients treated with selegiline and patients treated with placebo [20]. This observation suggests that side effects of selegiline are not substantial enough to cause patients to end therapy. Especially at higher doses, selegiline treatment may however harbour a potential risk for

dietary tyramine-provoked hypertensive crisis [32], since its metabolites metamphetamine and amphetamine are also capable to inhibit peripheral MAO-A [33,34], which is crucial for the metabolism of tyramine [35]. Before initiating selegiline treatment, it is therefore advisable to instruct patients to avoid excessive intake of tyramine-rich foods, such as aged cheese, tap beer, red wine and salami. It should also be noted that in the past there has been some controversy about the safety of selegiline after a study by the Parkinson's Disease Research Group of the United Kingdom had reported excess mortality in patients subjected to a combined treatment with levodopa and selegiline [36], which seemed to affect particularly those individuals with postural hypotension, frequent falls, confusion and dementia [37]. However, later meta-analysis found no significant difference in mortality between patients on MAO-B inhibitors and control patients and instead confirmed their good tolerability [20]. The safety profile of conventional selegiline may moreover be further improved by the use of its orally disintegrating form, which due to improved bioavailability can be administered at lower doses with comparable efficacy and produces lower concentrations of potentially troublesome metamphetamine metabolites by bypassing first-pass metabolism in the liver [38].

In contrast to selegiline, the second-generation MAO-B inhibitor rasagiline is metabolized to aminoindan, which is devoid of an amphetamine-like chemical scaffolding and is thus considered not to have vasoactive properties. Indeed, clinical studies demonstrated good tolerability of rasagiline treatment and found no difference in the frequency of cardiovascular and psychiatric adverse events between rasagiline and placebo treated patients [5,6,39,40]. The excellent side-effect profile of rasagiline has been recently confirmed in the Attenuation of Disease Progression with Azilect Given Once-daily (ADAGIO) trial, which showed no significant differences in adverse events between placebo-treated patients and study participants subjected to daily treatment with 1 mg or 2 mg rasagiline [7]. Moreover, a recently published tyramine challenge study has demonstrated that rasagiline selectively inhibits MAO-B and is not associated with increased tyramine sensitivity at the recommended daily dose of 1 mg [41].

Taken together, data from clinical trials is supportive of good tolerability and safety of MAO-B inhibitors as antiparkinsonian agents, which is a second argument for their use in early PD. Caution should be exercised when administering MAO-B inhibitors together with drugs that increase sympathetic tone, such as ephedrine and phenylephrine, in order to avert the risk of hypertensive crisis. Moreover, concomitant treatment with serotonergic analgesics, such as meperidine, tramadol, methadone and propoxyphene, should be generally avoided in order

to prevent a serotonin syndrome [35]. Caution is also advised when administering MAO-B inhibitors together with antidepressants that increase serotonin levels, such as selective serotonin reuptake inhibitors, imipraminics and serotonin-norepinephrine uptake inhibitors, although available studies suggest that the risk to cause serotonin toxicity due to concomitant treatment with antidepressants is rather low [42,43].

MAO-B inhibitors are easy to use

Whenever long-term administration of pharmacological agents becomes necessary, physicians need to ensure that the dosing regimen is not too complex in order to be followed by patients, since non-compliance may result in early discontinuation, underuse, overuse and irregular ingestion of medication. Previous smaller studies have demonstrated that therapy adherence in PD patients is suboptimal and approximates that reported in other chronic diseases [44,45]. In a larger European multi-center study initiated by Donald Grosset, we have been recently examining drug adherence in 112 PD patients for 4 weeks using electronic monitoring bottles, which recorded the date and time of cap opening [46]. In this study, 12.5% of PD patients took less than 80% of prescribed medication, which was associated with significantly poorer motor function and mobility [46]. Although overall total adherence to PD treatment was high, we observed considerable variation of medication intake between days and often irregular timing of medication intake, which argues against an early use of levodopa in PD, since inaccurate timing of levodopa intake may result in pulsatile dopaminergic stimulation and accelerate the development of motor complications [47]. Indeed, patients with motor fluctuations in our study had significantly lower total and timing adherence than nonfluctuators [46]. On the contrary, once daily drugs had significantly better adherence when compared with drugs prescribed more frequently, which strongly supports the usage of novel extended-release formulations of dopamine agonists or of MAO-B inhibitors, whereas the latter are additionally capable to provide a more sustained and continuous stimulation of the post-synaptic dopaminergic receptors by prolonging the half-life of dopamine in the basal ganglia.

Another possible obstacle to regular medication intake in PD patients may be dysphagia, which although more common in advanced stages can also be observed in early PD [48,49]. In patients with swallowing difficulties, PD treatment may be initiated with the orally disintegrating form of selegiline, which is nowadays available on the market as Otrassel[®], Xilopar[®] and Zelapar[®]. In contrast to conventional selegiline and other antiparkinsonian agents, orally disintegrating selegiline is refined by lyophilisation using Zydis technology[®] [50], which

ensures rapid dissolving in the mouth and facilitates pregastral (predominantly buccal) absorption. Patient preference for orally disintegrating selegiline has been evaluated in a single-dose, randomised, two-way cross-over study in 148 PD patients, in which about 30% were suffering from swallowing difficulties [51]. In this study, PD patients who had been previously treated with 10 mg of conventional selegiline as adjunctive therapy were transiently switched to a single dose of 5 mg of orally disintegrating selegiline or a placebo fast-dissolving formulation and asked for their preference. Most patients (61%) liked the novel formulation of selegiline, which was a significantly greater proportion than the null hypothesis of 50% ($p < 0.002$). Moreover, 67% of the patients with swallowing difficulties preferred orally disintegrating selegiline to conventional selegiline tablets [51]. These results indicate that alongside parenteral forms of dopamine agonists, such as transdermal rotigotine and subcutaneous apomorphine, orally disintegrating selegiline might be a worthwhile option for treatment in those PD patients, in whom swallowing difficulties already constitute a problem at the beginning of the disease.

MAO-B inhibitors potentially have disease-modifying capabilities

Despite marked advances in symptomatic treatment during recent decades, clinical studies in PD patients have so far failed to provide compelling proof for neuroprotective capabilities in most antiparkinsonian agents [52]. In the absence of disease-modifying therapies, symptomatic treatment can only transiently compensate for the progressive neurodegeneration in the nigrostriatal system and in non-mesencephalic brain regions, which will eventually lead to motor fluctuations, dyskinesias and intolerable disability in most PD patients [53]. Consequently, neuroprotective therapy that slows or even stops disease progression is considered a major unmet medical need in the treatment of PD [54].

Data from preclinical studies has redundantly suggested that MAO-B inhibitors may have neuroprotective properties. For example, previous studies demonstrated that selegiline is able to block the development of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity [55,56] and *in vivo* may protect mesencephalic dopaminergic neurons from glutamate receptor-mediated toxicity [57,58] and from toxicity induced by glutathione depletion [59]. Similar results were also obtained with rasagiline, which was found to increase survival in dopaminergic neurons [60,61] and to protect against neurotoxin-induced apoptotic cell death in SH-SY5Y cells [62,63]. Subsequent studies in animal models of PD also demonstrated *in vivo* that pre-treatment with selegiline or rasagiline is capable to

markedly attenuate the behavioural deficits arising from neurotoxic MPTP and 6-hydroxydopamine injections [64,65], thereby nourishing further hope that MAO-B inhibitors would also harbour disease-modifying capabilities in the clinical setting.

One of the earliest clinical studies to examine neuroprotective effects in MAO-B inhibitors has been the Deprenyl (= selegiline) and Tocopherol Antioxidative Therapy of Parkinson (DATATOP) trial, in which 800 patients with early PD were randomized to four treatment arms: 1) tocopherol placebo and selegiline placebo, 2) 2000 IU tocopherol per day and selegiline placebo, 3) tocopherol placebo and 10 mg selegiline per day and 4) 2000 IU tocopherol and 10 mg selegiline per day [4,66]. This study was prematurely terminated after a mean of 12 months when an interim analysis revealed that patients treated with selegiline required levodopa nine months later than individuals who were not randomized to selegiline treatment [66]. Although this delay in the onset of disability necessitating levodopa therapy was tempting to the conclusion that selegiline would be neuroprotective and had also been found in similar studies [9,18], final analysis of the DATATOP study demonstrated that the benefit of selegiline in delaying disability was related to a symptomatic relief of PD [4]. Moreover, long-term observation of the study cohort demonstrated that after an average of 8.2 years the mortality rate was unaffected by selegiline treatment, thus further questioning a putative disease-modifying effect of this substance [67].

More promising results have been found with rasagiline, which has been investigated in two double-blind, placebo-controlled clinical trials, which both utilized the delayed-start design in order to separate potential neuroprotective properties of rasagiline from its symptomatic effects [6,7]. In the TVP-1012 in early monotherapy for PD outpatients (TEMPO) study, 404 previously untreated patients with early PD were randomized to one of three treatment groups: 1) 1 mg rasagiline per day for 1 year, 2) 2 mg rasagiline per day for 1 year or 3) placebo for 6 months followed by 2 mg rasagiline per day for 6 months. The difference between early and delayed treatment on the total UPDRS after one year was about 2 points, which cannot be purely attributed to a symptomatic effect of rasagiline [6]. Moreover, results of an open-label extension of the TEMPO study recently demonstrated that early rasagiline treatment in comparison to delayed treatment provided long-term clinical benefit over years even in the face of treatment with other dopaminergic agents, which can only be explained by an enduring neuroprotective effect of rasagiline or an influence on compensatory mechanisms in early PD [68]. Disease-modifying effects of rasagiline have also been examined in the Attenuation

of Disease Progression with Azilect Given Once-daily (ADAGIO) study, which was performed in two phases, each lasting 36 weeks [7]. In the first phase, 1176 subjects were randomly assigned to one of four study groups: rasagiline at a dose of either 1 mg or 2 mg per day (the early-start groups) or corresponding placebo. In the second phase, the early-start groups continued to receive their assigned treatment while subjects in the placebo groups were switched to rasagiline at a dose of 1 mg or 2 mg per day (the delayed-start groups). Three end points had to be met in hierarchical fashion in order to declare positive results, which comprised 1) less worsening in the rate of change in the total UPDRS score between weeks 12 and 36 as compared with placebo, 2) less worsening in the total UPDRS score between baseline and week 72 in the early-start group than in the delayed-start group and 3) non-inferiority in the rate of worsening in the total UPDRS score between weeks 48 and 72 in the early-start group in comparison to the delayed-start group [7]. Rasagiline at a dose of 1 mg per day met all three pre-defined end points, which is consistent with a possible disease-modifying effect of this treatment. Surprisingly, results were negative for patients treated with rasagiline at a daily dose of 2 mg, since this dose failed to meet the second endpoint. However, ADAGIO investigators hypothesized that symptomatic effects of rasagiline 2 mg per day may have masked disease-modifying effects in this population of patients with very mild disease, which was supported by a post-hoc subgroup analysis revealing that the second endpoint was indeed met in those subjects, who were in the highest quartile of UPDRS scores at baseline [7]. Despite uncertainties arising from the ADAGIO study, the functional significance of its results and putative general concerns with the delayed-start design [69], it is important to note that the clinical data on neuroprotective effects of rasagiline are so far unrivalled in comparison to trials with other antiparkinsonian agents. Although previous studies have also suggested neuroprotective properties for levodopa [15] and for dopamine agonists [70,71] by using neuroimaging biomarkers as surrogate endpoint for disease progression, the significance of these findings remains rather questionable due to methodological difficulties and poor correlation between radiotracer imaging and the eventual clinical outcome [52,72]. On the contrary, the long-term clinical benefit that has been observed in the open-label extension of TEMPO eventually provides at least some scientific rationale for assuming disease-modifying effects of rasagiline in early PD, which may provide another good reason to favour MAO-B inhibitors for the initial treatment of PD.

Summary

Despite ongoing controversies among neurologists on how to initiate treatment in early PD there are compelling arguments for MAO-B inhibitors to be preferred in this situation. In clinical studies, they have shown to ameliorate symptoms of the disease, to delay the need for levodopa and to reduce the incidence of motor fluctuations. Furthermore, MAO-B inhibitors come with no substantial side effects and are easy to administer, which facilitates long-term adherence of patients to the therapy. In contrary to other antiparkinsonian agents such as levodopa and dopamine agonists, there is moreover growing and so far unrivalled clinical evidence for potential disease-modifying effects of MAO-B inhibitors in PD, which may eventually only be fully exploited by an early application from the very beginning of the disease. On the contrary, it needs to be acknowledged that the symptomatic efficacy of MAO-B inhibitors is clearly inferior to those of dopamine agonists and levodopa, which should be particularly considered if immediate and robust control of motor symptoms is warranted. In the future, head-to-head comparison of antiparkinsonian agents (such as in the ongoing PD MED trial) may allow an unbiased and patient-orientated assessment of the risk-benefit relationship in individual PD medications and eventually facilitate the decision on how to initiate treatment in early PD.

Authors' contributions

ML drafted the manuscript. HR critically revised the manuscript. Both authors read and approved the final manuscript.

Competing interests

ML has been funded by a research grant of the Center for Regenerative Therapies Dresden and received honoraria for presentations from Boehringer Ingelheim and GlaxoSmithKline. HR has been acting on Advisory Boards and received honoraria and research funds from Abbott, Bayer HealthCare, Boehringer Ingelheim, Cephalon, Desitin, GlaxoSmithKline, Merck Serono, Novartis, Orion, Pfizer, Teva/Lundbeck, UCB Pharma and Valeant.

Received: 7 March 2011 Accepted: 22 September 2011

Published: 22 September 2011

References

1. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad M, Larsen JP: **Epidemiology of Parkinson's disease.** *J Neurol* 2008, **255**(Suppl 5):18-32.
2. Grosset D, Taurah L, Burn DJ, MacMahon D, Forbes A, Turner K, Bowron A, Walker R, Findley L, Foster O, et al: **A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.** *J Neurol Neurosurg Psychiatry* 2007, **78**(5):465-469.
3. Schapira AH, Obeso J: **Timing of treatment initiation in Parkinson's disease: a need for reappraisal?** *Ann Neurol* 2006, **59**(3):559-562.
4. Parkinson Study Group: **Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease.** *N Engl J Med* 1993, **328**(3):176-183.
5. Parkinson Study Group: **A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.** *Arch Neurol* 2002, **59**(12):1937-1943.
6. Parkinson Study Group: **A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.** *Arch Neurol* 2004, **61**(4):561-566.

7. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, et al: **A double-blind, delayed-start trial of rasagiline in Parkinson's disease.** *N Engl J Med* 2009, **361**(13):1268-1278.
8. Allain H, Pollak P, Neukirch HC: **Symptomatic effect of selegiline in de novo Parkinsonian patients. The French Selegiline Multicenter Trial.** *Mov Disord* 1993, **8**(Suppl 1):S36-40.
9. Palhagen S, Heinonen EH, Hagglund J, Kaugesaar T, Kontants H, Maki-Ikola O, Palm R, Turunen J: **Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.** *Neurology* 1998, **51**(2):520-525.
10. Schrag A, Sampaio C, Counsell N, Poewe W: **Minimal clinically important change on the unified Parkinson's disease rating scale.** *Mov Disord* 2006, **21**(8):1200-1207.
11. Parkinson Study Group: **Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study.** *Jama* 1997, **278**(2):125-130.
12. Adler CH, Sethi KD, Hauser RA, Davis TL, Hammerstad JP, Bertoni J, Taylor RL, Sanchez-Ramos J, O'Brien CF: **Ropinireole for the treatment of early Parkinson's disease. The Ropinireole Study Group.** *Neurology* 1997, **49**(2):393-399.
13. Shannon KM, Bennett JP Jr, Friedman JH: **Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group.** *Neurology* 1997, **49**(3):724-728.
14. Parkinson Study Group: **A controlled trial of rotigotine monotherapy in early Parkinson's disease.** *Arch Neurol* 2003, **60**(12):1721-1728.
15. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K: **Levodopa and the progression of Parkinson's disease.** *N Engl J Med* 2004, **351**(24):2498-2508.
16. Hauser RA, Auinger P, Oakes D: **Levodopa response in early Parkinson's disease.** *Mov Disord* 2009, **24**(16):2328-2336.
17. Parkinson Study Group: **Effect of lazabemide on the progression of disability in early Parkinson's disease.** *Ann Neurol* 1996, **40**(1):99-107.
18. Tetrud JW, Langston JW: **The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.** *Science* 1989, **245**(4917):519-522.
19. Myllyla VV, Sotaniemi KA, Vuorinen JA, Heinonen EH: **Selegiline as initial treatment in de novo parkinsonian patients.** *Neurology* 1992, **42**(2):339-343.
20. Ives NJ, Stowe RL, Marro J, Counsell C, Macleod A, Clarke CE, Gray R, Wheatley K: **Monoamine oxidase type B inhibitors in early Parkinson's disease: meta-analysis of 17 randomised trials involving 3525 patients.** *BMJ* 2004, **329**(7466):593.
21. Myllyla VV, Sotaniemi KA, Hakulinen P, Maki-Ikola O, Heinonen EH: **Selegiline as the primary treatment of Parkinson's disease—a long-term double-blind study.** *Acta Neurol Scand* 1997, **95**(4):211-218.
22. Caraceni T, Musicco M: **Levodopa or dopamine agonists, or deprenyl as initial treatment for Parkinson's disease. A randomized multicenter study.** *Parkinsonism Relat Disord* 2001, **7**(2):107-114.
23. Rascol O, Brooks DJ, Korczyn AD, De DPP, Clarke CE, Lang AE: **A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.** *N Engl J Med* 2000, **342**:1484-1491.
24. Parkinson Study Group CALM Cohort Investigators: **Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.** *Arch Neurol* 2009, **66**(5):563-570.
25. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, et al: **Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.** *Arch Neurol* 2004, **61**(7):1044-1053.
26. Poewe WH, Lees AJ, Stern GM: **Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study.** *Neurology* 1986, **36**(11):1528-1530.
27. Martin WR, Sloan JW, Sapira JD, Jasinski DR: **Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man.** *Clin Pharmacol Ther* 1971, **12**(2):245-258.
28. Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ: **Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.** *J Neurol Neurosurg Psychiatry* 1997, **63**(2):228-234.
29. Yasar S, Goldberg SR, Goldberg SR: **Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research.** *J Neural Transm Suppl* 1996, **48**:61-73.
30. Yasar S, Justinova Z, Lee SH, Stefanski R, Goldberg SR, Tanda G: **Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].** *J Pharmacol Exp Ther* 2006, **317**(1):387-394.
31. Gill JR Jr, Masson DT, Bartter FC: **Effects of hydroxyamphetamine (paredrine) on the function of the sympathetic nervous system in normotensive subjects.** *J Pharmacol Exp Ther* 1967, **155**(2):288-295.
32. Schulz R, Antonin KH, Hoffmann E, Jedrychowski M, Nilsson E, Schick C, Bieck PR: **Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.** *Clin Pharmacol Ther* 1989, **46**(5):528-536.
33. Mantle TJ, Tipton KF, Garrett NJ: **Inhibition of monoamine oxidase by amphetamine and related compounds.** *Biochem Pharmacol* 1976, **25**(18):2073-2077.
34. Suzuki O, Hattori H, Asano M, Oya M, Katsumata Y: **Inhibition of monoamine oxidase by d-methamphetamine.** *Biochem Pharmacol* 1980, **29**(14):2071-2073.
35. Chen JJ, Swope DM, Dashtipour K: **Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.** *Clin Ther* 2007, **29**(9):1825-1849.
36. Lees AJ: **Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.** *BMJ* 1995, **311**(7020):1602-1607.
37. Ben-Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, Lees AJ: **Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.** *BMJ* 1998, **316**(7139):1191-1196.
38. Löhle M, Storch A: **Orally disintegrating selegiline for the treatment of Parkinson's disease.** *Expert Opin Pharmacother* 2008, **9**(16):2881-2891.
39. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E: **Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.** *Lancet* 2005, **365**(9463):947-954.
40. Parkinson Study Group: **A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.** *Arch Neurol* 2005, **62**(2):241-248.
41. Goren T, Adar L, Sasson N, Weiss YM: **Clinical pharmacology tyramine challenge study to determine the selectivity of the monoamine oxidase type B (MAO-B) inhibitor rasagiline.** *J Clin Pharmacol* 2010, **50**(12):1420-1428.
42. Perez-Lloret S, Rascol O: **Safety of rasagiline for the treatment of Parkinson's disease.** *Expert Opin Drug Saf* 2011, **10**(4):633-643.
43. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C: **Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.** *Neurology* 1997, **48**(4):1070-1077.
44. Leopold NA, Polansky M, Hurka MR: **Drug adherence in Parkinson's disease.** *Mov Disord* 2004, **19**(5):513-517.
45. Grosset KA, Bone I, Grosset DG: **Suboptimal medication adherence in Parkinson's disease.** *Mov Disord* 2005, **20**(11):1502-1507.
46. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, et al: **Adherence to antiparkinson medication in a multicenter European study.** *Mov Disord* 2009, **24**(6):826-832.
47. Stocchi F: **The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.** *Parkinsonism Relat Disord* 2009, **15**(Suppl 1):S9-S15.
48. Nilsson H, Ekberg O, Olsson R, Hindfelt B: **Quantitative assessment of oral and pharyngeal function in Parkinson's disease.** *Dysphagia* 1996, **11**(2):144-150.
49. Potulska A, Friedman A, Krockli L, Spychala A: **Swallowing disorders in Parkinson's disease.** *Parkinsonism Relat Disord* 2003, **9**(6):349-353.
50. Virely P, Yarwood R: **Zydis: a novel, fast dissolving dosage form.** *Manuf Chem* 1990, **61**: 36-37.
51. Clarke A, Johnson ES, Mallard N, Corn TH, Johnston A, Boyce M, Warrington S, MacMahon DG: **A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition.** *J Neural Transm* 2003, **110**(11):1257-1271.

52. Löhle M, Reichmann H: **Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.** *J Neurol Sci* 2010, **289**(1-2):104-114.
53. Hely MA, Morris JG, Reid WG, Trafficante R: **Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.** *Mov Disord* 2005, **20**(2):190-199.
54. Olanow CW: **The scientific basis for the current treatment of Parkinson's disease.** *Annu Rev Med* 2004, **55**:41-60.
55. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD: **Pargyline and deprenyl prevent the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys.** *Eur J Pharmacol* 1984, **106**(1):209-210.
56. Heikkilä RE, Manzino L, Cabbat FS, Duvoisin RC: **Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.** *Nature* 1984, **311**(5985):467-469.
57. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW: **L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.** *J Neurochem* 1997, **68**(1):33-39.
58. Mytilineou C, Radcliffe PM, Olanow CW: **L-(-)-desmethylelegriline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.** *J Neurochem* 1997, **68**(1):434-436.
59. Mytilineou C, Leonardi EK, Radcliffe P, Heinonen EH, Han SK, Werner P, Cohen G, Olanow CW: **Deprenyl and desmethylelegriline protect mesencephalic neurons from toxicity induced by glutathione depletion.** *J Pharmacol Exp Ther* 1998, **284**(2):700-706.
60. Finberg JP, Takeshima T, Johnston JM, Commissiong JW: **Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.** *Neuroreport* 1998, **9**(4):703-707.
61. Goggi J, Theofilopoulos S, Riaz SS, Jauniaux E, Stern GM, Bradford HF: **The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.** *Neuroreport* 2000, **11**(18):3937-3941.
62. Maruyama W, Akao Y, Youdim MB, Naoi M: **Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022.** *J Neural Transm Suppl* 2000, **60**: 171-186.
63. Naoi M, Maruyama W, Youdim MB, Yu P, Boulton AA: **Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase.** *Inflammopharmacology* 2003, **11**(2):175-181.
64. Blandini F, Armentero MT, Fancelli R, Blaugrund E, Nappi G: **Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.** *Exp Neurol* 2004, **187**(2):455-459.
65. Kupsch A, Sautter J, Gotz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH: **Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.** *J Neural Transm* 2001, **108**(8-9):985-1009.
66. Parkinson Study Group: **Effect of deprenyl on the progression of disability in early Parkinson's disease.** *N Engl J Med* 1989, **321**(20):1364-1371.
67. Parkinson Study Group: **Mortality in DATATOP: a multicenter trial in early Parkinson's disease.** *Ann Neurol* 1998, **43**(3):318-325.
68. Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ: **Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease.** *Mov Disord* 2009, **24**(4):564-573.
69. Clarke CE: **Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?** *Mov Disord* 2008, **23**(6):784-789.
70. Parkinson SG: **Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.** *Jama* 2002, **287**(13):1653-1661.
71. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, et al: **Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study.** *Ann Neurol* 2003, **54**(1):93-101.
72. Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, et al: **The role of radiotracer imaging in Parkinson disease.** *Neurology* 2005, **64**:208-215.

Pre-publication history

The pre-publication history for this paper can be accessed here:
<http://www.biomedcentral.com/1471-2377/11/112/prepub>

doi:10.1186/1471-2377-11-112

Cite this article as: Löhle and Reichmann: **Controversies in Neurology: why monoamine oxidase B inhibitors could be a good choice for the initial treatment of Parkinson's disease.** *BMC Neurology* 2011 **11**:112.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- **Convenient online submission**
- **Thorough peer review**
- **No space constraints or color figure charges**
- **Immediate publication on acceptance**
- **Inclusion in PubMed, CAS, Scopus and Google Scholar**
- **Research which is freely available for redistribution**

Submit your manuscript at
www.biomedcentral.com/submit

